Affiliations: [a] Department of Neurology, Academic Medical Centre, Amsterdam, The Netherlands | [b] Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands | [c] Department of Psychiatry, Free University, Amsterdam, The Netherlands
Correspondence:
[*]
Correspondence to: Ben Schmand, Academic Medical Centre, Department of Neurology, H2, PO Box 22660, 1100 DD Amsterdam, The Netherlands. Tel.: +31 20 566 3590; Fax: +31 20 566 9217; E-mail: [email protected].
Note: [1] Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http://www.loni.ucla.edu/ADNI). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. ADNI investigators include (complete listing available at http://adni.loni.ucla.edu/research/active-investigators/).
Abstract: Using the database of the Alzheimer's Disease Neuroimaging Initiative, we examined the value of neuropsychological assessment, structural magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) biomarkers, and FDG-PET scanning with respect to prediction of conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD). We tested the hypothesis that CSF biomarkers and FDG-PET would lose prognostic value when applied in patients older than 75 years, whereas MRI and neuropsychological testing would not. At baseline 175 patients had MCI, mostly amnestic. They were followed during a mean of 2.7 years, and 81 patients converted to AD after a mean of 1.6 years. Logistic regression analyses showed that neuropsychological assessment and MRI variables predicted conversion with 63 to 67% classification success both in patients younger and older than 75 years, while CSF biomarkers attained this success rate only in patients younger than 75 years. For FDG-PET, this rate was 57% in the total sample. We conclude that the diagnostic yield of different techniques in predicting conversion from MCI to AD is moderate, and that it is affected by age of the subject under study. MRI and neuropsychological assessment remain informative in patients older than 75 years, unlike CSF biomarkers.
Keywords: Alzheimer's disease, amyloid, cerebrospinal fluid, FDG-PET, mild cognitive impairment, MRI, neuropsychological tests, tau protein
